Publication | Closed Access

Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trial

Antimicrobial SusceptibilityAntibioticsSkin-structure InfectionsAcute Bacterial SkinNon-inferiority TrialAntimicrobial ChemotherapyInfection ControlDermatologyMedicineClinical MicrobiologyAntimicrobial Resistance